Baird lowered the firm’s price target on Iovance Biotherapeutics to $24 from $26 and keeps an Outperform rating on the shares. The firm said they reported 2Q24 results. This was not the beat Baird was looking for, as a big Proleukin stocking number drove a topline beat, while 2Q24 Amtagvi sales were below expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
- Iovance Biotherapeutics put volume heavy and directionally bearish
- IOVA Earnings this Week: How Will it Perform?
- Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
- Iovance Biotherapeutics downgraded to Neutral from Overweight at Piper Sandler